Regulation of ANP clearance receptors by EGF in mesangial
cells from NOD mice
Sandrine
Placier,
Xavier
Bretot,
Nicole
Ardaillou,
Jean-Claude
Dussaule, and
Raymond
Ardaillou
Institut National de la Santé et de la Recherche
Médicale U-489, Hôpital Tenon, 75020 Paris, France
 |
ABSTRACT |
Mesangial cells from nonobese diabetic
(NOD) mice (D-NOD) that develop diabetes at 2-4 mo express an
increased density of atrial natriuretic peptide (ANP) clearance
receptors [natriuretic peptide C receptor (NPR-C)] and produce less
GMP in response to ANP than their nondiabetic counterparts (ND-NOD).
Our purpose was to investigate how both phenotypic characteristics were
regulated. Epidermal growth factor (EGF) and heparin-binding (HB)-EGF,
but not platelet-derived growth factor or insulin-like growth factor I,
inhibited 125I-ANP binding to ND-NOD and D-NOD mesangial
cells, particularly in the latter. NPR-C density decreased with no
change in the apparent dissociation constant, and there was also a
decrease in NPR-C mRNA expression. The EGF effect depended on
activation of its receptor tyrosine kinase but not on that of protein
kinase C, mitogen-activated protein kinases, or phosphoinositide-3
kinase. Activation of activator protein-1 (AP-1) was necessary, as
shown by the inhibitory effect of curcumin and the results of the
gel-shift assay. The cGMP response to physiological concentrations of
ANP was greater in EGF-treated D-NOD cells. These studies suggest that
EGF potentiates the ANP glomerular effects in diabetes by inhibition of
its degradation by mesangial NPR-C via a mechanism involving AP-1.
diabetes mellitus; natriuretic peptide C receptor; guanosine
3',5'-cyclic monophosphate; growth factor; glomerulus; atrial
natriuretic peptide; epidermal growth factor
 |
INTRODUCTION |
RENAL
VASODILATION AND HYPERFILTRATION occur early in insulin-dependent
diabetes mellitus (17). Several factors contribute to
hyperfiltration, among which increased renal plasma flow plays the
major role. However, at any given renal plasma flow, glomerular filtration rate is greater in diabetic patients than in control subjects, indicating that the parameters of the glomerular
microcirculation, essentially the glomerular capillary pressure and the
ultrafiltration coefficient, are also modified (28). The
latter parameter is considered to largely depend on the contractile
status of mesangial cells (26). In addition, altered
mesangial cell growth is one of the early abnormalities detected after
the onset of diabetes with an initial cell proliferation and a
subsequent glomerular hypertrophy that can, in turn, increase the
available surface area for filtration (41).
We showed recently that atrial natriuretic peptide (ANP) clearance
receptors [natriuretic peptide C receptor (NPR-C)] were overexpressed
in cultured mesangial cells from nonobese diabetic (NOD) mice that
developed diabetes at 2-4 mo of age (D-NOD) in contrast to
mesangial cells from mice of the same strain that remained
normoglycemic (ND-NOD). Overexpression of NPR-C mRNA and protein in
D-NOD cells was associated with a decreased cGMP response to ANP and
natriuretic peptide C, which could be attributable to a lesser
availability of intact natriuretic peptides in the medium due to their
more marked degradation (4). NPR-C expression is submitted
to a complex regulation, in which are implied growth factors (31,
19),
2-adrenergic agonists (22), the
natriuretic peptides themselves (43), other vasoactive
peptides (11), and steroids (3). Of note,
heparin-binding epidermal growth factor (HB-EGF) is expressed by
mesangial cells and has been shown to be involved in mesangial cell
proliferation in experimental glomerulonephritis (36).
Furthermore, EGF receptors (EGF-R), which also recognize transforming
growth factor-
and HB-EGF (40), are overexpressed in
experimental diabetes (21). For all these reasons, we
thought it was of interest to examine the effects of growth factors,
especially EGF, on NPR-C expression in mesangial cells from diabetic
mice. Our data demonstrate that EGF, but neither platelet-derived
growth factor (PDGF) nor insulin-like growth factor I (IGF-I),
downregulates NPR-C mRNA and protein via a mechanism implicating EGF-R
tyrosine kinase and the transcription factor activator protein-1
(AP-1). Moreover, EGF potentiates the ANP-dependent cGMP response,
suggesting its possible implication in the biological effects of this hormone.
 |
METHODS |
Mesangial cell culture.
Two lines of NOD mesangial cells were studied that were propagated from
glomeruli of 4-mo-old female diabetic (i.e., D-NOD) and nondiabetic
(i.e., ND-NOD) mice. These cell lines were kindly provided by L. and G. Striker (Miami, FL) and were studied between passages 15 and
35. They were cultured as previously described (6) in dishes precoated with fibronectin in defined medium (basal medium): DMEM-Ham's F-12 (1:2, vol/vol) supplemented with 20 mM
HEPES, 20% fetal calf serum, and 2 mM glutamine and containing 6 mM
glucose. Cells were maintained in a 95% O2-5%
CO2 atmosphere.
Binding studies.
After having reached confluence, cells were deprived of serum during
24 h and either exposed or not exposed during this period to EGF
(5 or 10 ng/ml), PDGF (10 ng/ml), IGF-I (10 ng/ml), or phorbol
12-myristate 13-acetate (PMA; 0.1 µM). The effect of 20% serum was
also studied. In addition to these studies, the effects of the
incubation time and of the concentrations of EGF or HB-EGF were also examined.
Binding was performed at the end of the incubation period in Hanks'
solution supplemented with 10 mM HEPES, pH 7.4, containing the
following concentrations of protease inhibitors: 2 mg/ml bacitracin, 0.1 µM aprotinin, 1 µM leupeptin, 0.1 µM pepstatin A, 10 µM
thiorphan, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM EDTA, and 1 mg/ml BSA. Binding experiments were performed in the presence of
125I-ANP as the ligand at 4°C for 4 h. At the end of
the incubation period, the medium was discarded, and cells were washed
three times with 1 ml of ice-cold 0.16 M NaCl. Then, cells were
solubilized in 1 M NaOH, and cell-associated radioactivity was counted
in a gamma counter. Binding experiments were performed by either saturation analysis with increasing concentrations (20-500 pM) of
125I-ANP or other studies were done with a fixed (50 pM)
concentration of 125I-ANP. In competitive binding
experiments, increasing concentrations (from 1 pM to 0.5 µM) of ANP
or 4---23 C-ANP, a specific ligand of NPR-C, were added. Nonspecific
binding was determined in the presence of 1 µM unlabeled ANP and was
<10%. Specific binding was calculated as the difference between total
and nonspecific binding. Results of the saturation-binding experiments
were analyzed by Scatchard's transformation of the data using the
Ligand software program (27). This allowed the apparent
dissociation constant (KD) and the number of
sites (Bmax) to be calculated. Results of the competitive
inhibition studies were analyzed by Hill's transformation of the data
to precisely determine the concentration corresponding to
IC50. Results were expressed as femtomoles of 125I-ANP bound per milligram of protein. The amount of
protein per well was measured by the Bradford method using BSA as the
standard (9).
cGMP determination.
After either pretreatment or no pretreatment with EGF (5 ng/ml) during
24 h in serum-free medium, cells were incubated with increasing
concentrations of ANP over 5 min at 37°C. At the end of the
incubation period, the medium was collected and put aside. Then, cell
cGMP was extracted with ethanol-formic acid (5:95, vol/vol). After a
30-min extraction, the supernatant was collected and pooled with the
medium. The pH of the resulting solution was adjusted to 6.0, and
cGMP was measured by radioimmunoassay as previously described
(5). To increase assay sensitivity, standards and
samples were acetylated using triethylamine and acetic anhydride (2:1, vol/vol). Results are expressed as femtomoles of cGMP per milligram of cell protein.
Cell proliferation studies.
After they had reached confluence, cells were incubated for 24 h
at 37°C in serum-free medium. Thereafter, cells were exposed for
24 h to EGF (5 ng/ml) or to 20% serum as a
proliferation control and then incubated with 0.1 µM ANP for 1 h
before [3H]thymidine (2 µCi/well) was added
for an additional period of 6 h. At the end of the incubation,
cells were washed successively twice with ice-cold 0.15 M NaCl and
three times with 10% cold trichloroacetic acid. Cells were then lysed
with cold 1 M sodium hydroxide for 18 h. Radioactivity of the
lysates was measured by liquid scintillation spectrometry after pH was
adjusted to 7.0 with 11.2 M hydrochloric acid, and
[3H]thymidine uptake was expressed as counts per minute
per milligram of cell protein.
Preparation of complementary RNA probes.
NPR-C, HB-EGF, EGF-R, and
-actin probes were prepared from cells
from NOD mice by RT-PCR using specific primers that were designed
according to the respective published sequences of their genes
(16, 1, 7, 2). These primers were as follows: CAAGCATACTCGTCCCTCCAAACA (NPR-C, upstream) and
CTCTTGGGTGCCTGCTTCAGTGTC (NPR-C, downstream);
AAATACCGCAAGCTCGAGAA (HB-EGF, upstream) and GATCCCTGCACTCTGACCAT
(HB-EGF, downstream); ATGTCCTCATTGCCCTCAAC (EGF-R, upstream) and
GGCAGTTCTCCTCTC CTCCT (EGF-R, downstream); and
CAAGGTGTGATGGTGGGAAT (
-actin, upstream) and
GTCATCTT TTCACGGTTGGC (
-actin, downstream). The
corresponding expected fragment lengths were 350, 378, 360, and 220 bp
for NPR-C, HB-EGF, EGF-R and
-actin, respectively. PCR products were
purified by using a Quiaquick PCR purification kit and sequenced. Ten
to twenty-five nanograms of PCR products were then ligated using a
Lign'scribe kit (Ambion, Austin, TX) with T7 promoter, T4 DNA ligase,
and gene-specific primers. A second PCR was prepared. Synthesis of an
antisense complementary RNA probe was carried out using an in vitro
transcription kit (Ambion). Incubation of 50 ng of probe with T7 RNA
polymerase and [
-32P]UTP (30 TBq/mmol, 1.85 MBq for
NPR-C, HB-EGF, and EGF-R, 0.92 MBq plus 6.25 µM unlabeled UTP for
-actin) was performed for 1 h at 37°C. Probes were then
purified by electrophoresis on 5% polyacrylamide gels containing 8 M urea.
RNase protection assay.
NOD cells were incubated or not incubated with EGF (5 ng/ml) during 2 or 4 h in the serum-free medium. Whenever needed, pharmacological inhibitors, including PD-98059 (15), a selective inhibitor
of mitogen-activated protein (MAP) kinase extracellular
signal-regulated kinase (ERK)-1 (MEK-1), tyrphostin AG-1478
(24), a potent and specific inhibitor of EGF-R tyrosine
kinase, GF-109203X (38), a selective inhibitor of protein
kinase C (PKC), curcumin (32), a blocker of AP-1
activation, or wortmannin (39), an inhibitor of
phosphatidylinositol 3-kinase (PI3-kinase), were added to the medium 15 min before EGF and maintained in the medium with EGF for 2 h. At
the end of the incubation period, RNase was extracted by using TRIzol
reagent (GIBCO-BRL, Grand Island, NY). Five to twenty micrograms of RNA
were hybridized with 2 × 105 counts per minute (cpm)
NPR-C, HB-EGF, or EGF-R probes and 1 × 105 cpm
-actin probes using an RNA assay kit (Ambion). The mixture was
incubated at 50°C for 16 h. Nonannealing nucleic acid was digested with RNase A/T1. The protected fragment was
electrophoresed on 5% polyacrylamide gels containing 8 M urea at 300 V. Gels were exposed for 8-48 h to Fuji X-ray film. Quantitation
of the bands was performed by densitometry (Imager Appligene,
Pleasanton, CA) using
-actin as a control.
Immunoprecipitation and immunoblotting.
After incubation for 10 min with EGF (5 ng/ml) and curcumin (20 µM)
separately or in combination, the degree of phosphorylation of EGF-R
was evaluated according to Iwasaki et al. (20). In brief,
mesangial cells were lysed in an appropriate lysis buffer and incubated
overnight at 4°C in the presence of a rabbit polyclonal anti-EGF-R
antibody. Immunocomplexes were adsorbed onto protein G-Sepharose and
then washed three times. The proteins were resolubilized in the loading
buffer, and an amount equal to 20 µg was submitted to immunoblotting.
After the membrane had been initially treated with either the EGF-R
antibody or a mouse monoclonal phosphotyrosine antibody and then with
the peroxidase-coupled rabbit IgG or mouse IgG antibody,
respectively, the immunoreactive proteins were detected with the enhanced chemiluminescence system. The degree of
phosphorylation of EGF-R was expressed as the ratio of the
phosphorylated EGF-R to the total EGF-R signal.
Preparation of nuclear extracts and gel mobility-shift assays.
Nuclear extracts were prepared according to the procedure of Dignam et
al. (14) from NOD-D mesangial cells that had been treated
by EGF (5 ng/ml) with or without curcumin (20 µM) for 1 h at
37°C. Double-stranded oligonucleotide corresponding to the AP-1 site
(CGCTTGATGACTCAGCCGGAA) and labeled with [
-32P]2'
deoxynucleoside-5' triphosphate was used as a probe in the gel-shift
assay. Nuclear extracts were mixed with binding buffer, glycerol,
Igepal, poly(dI-dC), and 32P-labeled DNA according to the
specifications of the band-shift assay kit. After incubation at room
temperature for 30 min, the reaction mixtures were loaded on 6%
polyacrylamide gels in Tris-borate-EDTA buffer and electrophoresed at
150 V for 3 h. Gels were then exposed to X-ray film with
intensifying screens.
Materials.
Materials and their sources are as follows: rat ANP(1---28) and 4---23
C-ANP (Peninsula Laboratories, Belmont, CA); PD-98059, GF-109203X, and
AG-1478 (Calbiochem, La Jolla, CA);
(3-[125I]iodotyrosyl28) ANP (rat, 74 TBq/mmol), [
-32P]UTP (30 TBq/mmol), and
125I-cGMP (74 TBq/mmol) (Radiochemical Center, Amersham,
Little Chalfont, Buckinghamshire, UK); anti-cGMP antibody (Institut
Pasteur, Paris, France); rabbit polyclonal anti-EGF-R antibody (Santa
Cruz Laboratories, Santa Cruz, CA); mouse monoclonal
anti-phosphotyrosine antibody (Chemicon, Temecula, CA); an in vivo
transcription kit (Maxiscript), RNase protection assay (RPA III), and
Lign'scribe kit (Ambion); a band-shift assay kit for characterization
of DNA-binding proteins and enhanced chemiluminescence kit for
immunoblotting (Amersham Pharmacia Biotech); oligo-dT primers and
random primers, 2' deoxynucleoside-5' triphosphate, Taq DNA
polymerase, and Moloney murine leukemia virus RT (GIBCO Life
Technologies, Cergy-Pontoise, France); oligonucleotide primers specific
for NPR-C, HB-EGF, EGF-R, and actin (Genset Oligos, Paris, France); and
a Quiaquick PCR purification kit (Quiagen, Courteboeuf, France). The
sequencing of PCR products was made by Euro Sequences Gene Service
(Montigny le Bretonneux, France). Cell culture media and cell culture
supplies were from GIBCO Life Technologies. All other reagents
including curcumin and wortmannin were from Sigma (St. Louis, MO).
Statistics.
Experiments comparing ND-NOD and D-NOD cells were done in parallel on
the same day with identical protein contents and at the same passage.
Results are expressed as means ± SE. Statistical comparison of
means was performed by using Student's t-test for unpaired
values and analysis of variance.
 |
RESULTS |
Effects of EGF, HB-EGF, PMA, PDGF, IGF-I and serum on NPR-C
receptors in D-NOD and ND-NOD mouse mesangial cells.
125I-ANP binding was considered to reflect essentially
NPR-C density in the following experiments because we demonstrated
previously that this receptor type represented 90% of the total NPR in
NOD mesangial cells (4). We first confirmed our previously
published finding that NPR-C density is much greater in D-NOD (617 ± 124 fmol/mg protein) than in ND-NOD (138 ± 41 fmol/mg protein)
mesangial cells (Fig. 1). Pretreatment of
the cells during 24 h with PMA (0.1 µM), serum (20%) or EGF (5 ng/ml) inhibited 125I-ANP binding in D-NOD and ND-NOD cells
(P < 0.01). However, the effect was much more marked
in D-NOD cells whatever the mode of expression selected (absolute or
relative difference). Inhibitions amounted to 82, 86, and 70% with
PMA, serum, and EGF, respectively, in D-NOD cells whereas they were
limited to 37 and 34% with PMA and EGF, respectively, in ND-NOD cells.
Only the inhibitory effect of serum was close in both cell types (86 and 76% in D-NOD and ND-NOD cells, respectively). Because of this more
marked effect of EGF in D-NOD cells, the subsequent binding experiments
were all performed using this cell type. Our first goal was to verify whether the inhibitory effect of EGF was specific for this growth factor or was merely associated with a status of dedifferentiation caused by EGF-induced proliferation. Therefore, we examined the effects
of other mitogenic cytokines such as PDGF and IGF-I. Both agents (10 ng/ml) did not significantly modify 125I-ANP binding
(904 ± 28 fmol/mg for PDGF and 985 ± 38 fmol/mg for IGF-I
vs. 956 ± 31 fmol/mg for control). We then analyzed more
thoroughly the influence of EGF on 125I-ANP binding. The
inhibitory effect of EGF increased with time (P < 0.01) when expressed as a percentage of the control value (Fig.
2). Indeed, 125I-ANP binding
under control conditions progressively increased over the period of
study (24-72 h) whereas it persisted at the same low level when
cells had been treated with EGF (5 ng/ml). Of note, the control binding
value at 24 h corresponded to a longer period of serum deprivation
(48 h) because the cells studied had been previously incubated in a
serum-free medium during 24 h. This explains why this control
value was higher than that observed in the other experiments. The
inhibitory effect of EGF increased as a function of the dose studied,
from 1 to 5 ng/ml (P < 0.01). It was the same or
slightly less marked when EGF concentration was increased up to 10 ng/ml. HB-EGF was studied at the same molar concentrations as EGF. It
also produced a dose-related inhibitory effect on 125I-ANP
binding over the range of concentrations studied (1.5-7.5 ng/ml).
However, HB-EGF was less potent than EGF on a molar basis. For example,
0.8 nM of EGF (5 ng/ml) produced a decrease in 125I-ANP
binding of 75% whereas the same molar concentration of HB-EGF (7.5 ng/ml) produced only a decrease of 52% (Fig.
3).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of phorbol 12-myristate 13-acetate (PMA; 0.1 µM), serum (20%), and epidermal growth factor (EGF; 5 ng/ml) on the
specific binding of 125I-labeled atrial natriuretic peptide
(ANP) to mesangial cells from nonobese diabetic (NOD) mice after 24-h
treatment. Cells from nondiabetic (ND-NOD; A) and diabetic
(D-NOD; B) mice were studied. Each bar represents the
mean ± SE of 4-6 values. Two-way (cell type, treatment)
analysis of variance showed a significant effect of each of these 2 factors and a significant interaction between them. Note the difference
in scale between A and B. C, control.
*P < 0.05 and **P < 0.01 vs.
control.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Time course of the EGF-sensitive specific
125I-ANP binding to mesangial cells from D-NOD mice. Each
bar represents the mean ± SE of 6 values. There was a significant
effect of EGF at each time studied. **P < 0.01 vs.
control.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of increasing concentrations of EGF (A) or
heparin-binding (HB)-EGF (B) on the specific
125I-ANP binding to mesangial cells from D-NOD mice after
24-h treatment. Each bar represents the mean of 6-10 values. The
effects of EGF and HB-EGF were significant at all the concentrations
studied. **P < 0.01 vs. 0 concentration.
|
|
To evaluate whether EGF modified the NPR-C density (Bmax)
or the apparent dissociation constant value (KD)
of ANP for its receptor, saturation binding experiments were performed,
and the data obtained were transformed according to Scatchard. The
results observed under control conditions were in accordance with our previously published findings (4). There was an apparent
single group of receptor sites with a Bmax of 1,411 ± 287 fmol/mg and a KD value of 365 ± 138 pM. Pretreatment of the cells by EGF (5 ng/ml) during 24 h did not
significantly modify the KD value (208 ± 38 pM) whereas there was a marked decrease (P < 0.05)
in Bmax (351 ± 59 fmol/mg) (Fig.
4). Competitive inhibition studies
confirmed these results. In the absence of unlabeled ANP,
125I-ANP binding was three times greater under control
conditions than after treatment with 5 ng/ml EGF. Such a decrease in
binding in EGF-treated cells was also observed at increasing
concentrations of unlabeled ANP up to 1 nM (Fig.
5). Hill's transformation of the data
showed that both transformed straight lines were almost superimposed,
suggesting that the calculated IC50 were close. The latter
values were in the same range as the KD values
derived from the saturation binding experiments (360 vs. 365 pM under control conditions; 114 vs. 208 pM in EGF-treated cells). C-ANP (4---23) was also a potent inhibitor of 125I-ANP binding.
However, the residual binding in the presence of 1 µM of unlabeled
peptide was slightly greater with 4---23 C-ANP than with ANP. This
difference, roughly amounting to 10% of ANP maximum binding,
represented the fraction corresponding to NPR-A receptors that
recognize ANP but not 4---23 C-ANP. This fraction was not apparently
modified by EGF (results not shown).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
Specific binding at equilibrium of 125I-ANP to
mesangial cells from D-NOD mice as a function of 125I-ANP
concentration in the medium with or without pretreatment of the cells
by EGF (5 ng/ml) during 24 h. Each point is the mean of 3 values.
Inset: Scatchard transformation of both curves. It allowed
the dissociation constant (KD; 132 and 100 pM)
and no. of sites (Bmax; 465 and 1,234 fmol/mg protein with
and without EGF pretreatment, respectively) to be calculated. One of
three representative experiments is shown.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Competitive inhibition of 125I-ANP binding to
mesangial cells from D- NOD mice in the presence of increasing
concentrations of unlabeled ANP with or without pretreatment of the
cells by EGF (5 ng/ml) during 24 h. Each point is the mean of 3 values. Inset: Hill transformation of both curves. It
allowed IC50 of 114 and 360 pM to be calculated with and
without EGF, respectively.
|
|
We also verified that the decrease in NPR-C density was not associated
with a decrease in cell viability by measuring
[3H]thymidine incorporation in D-NOD mesangial cells
under control conditions and in the presence of EGF (5 ng/ml for
24 h). We found the expected marked increase in
[3H]thymidine incorporation (22.5 ± 2.1 vs.
6.4 ± 0.6 cpm/µg protein with and without EGF, respectively,
where cpm is counts/min; P < 0.001), indicating a
normal proliferative response of the cells.
Effect of ANP on cGMP production by NOD mesangial cells pretreated
or not pretreated with EGF.
ANP stimulated cGMP production in untreated D-NOD mesangial cells in a
dose-dependent manner over the range of concentrations studied (100 pM-10 nM). The increase at 10 nM was 10 times the basal value. A
similar pattern was observed with EGF-treated cells. EGF treatment of
D-NOD cells did not modify the basal production of cGMP. However, the
cGMP response to increasing concentrations of ANP was more marked when
cells had been pretreated with EGF. Analysis of the data shown in Table
1 indicated that the effect of EGF was
significant (P < 0.01). There was also a significant interaction (P < 0.01) between EGF and ANP
concentration effects showing that the degree of EGF effect changed
with the concentration of ANP studied. Indeed, it was high (+39.5%) at
1 nmol/l of ANP but attenuated (+12.4%) at 10 nmol/l. To confirm this
view, we also studied the effect of a much higher concentration of ANP (500 nmol/l). At this concentration, there was no significant effect of
EGF on the cGMP response to ANP (results not shown).
Effect of EGF on NPR-C mRNA.
In accordance with our previously published study (4),
NPR-C mRNA was detected by RNase protection assay in D-NOD mesangial cells. Pretreatment of the cells by EGF (5 ng/ml) during 2 or 4 h
markedly diminished the expression of NPR-C mRNA (P < 0.05). There was a decrease of ~40% of the ratio of NPR-C to
-actin mRNA at the two times studied (Fig.
6). This inhibitory effect of EGF was
unchanged in the presence of PD-98059 (50 µM), an inhibitor of the
MAP kinase cascade, GF-109203X (1 µM), an inhibitor of PKC,
and wortmannin (0.1 µM), an inhibitor of phosphoinositide 3-kinase.
In contrast, the effect of EGF was reduced or abolished in the presence
of AG-1478 (250 nM), an inhibitor of EGF receptor tyrosine kinase
(P < 0.01), and curcumin (20 µM), a blocker of activation of the transcription factor AP-1 (P < 0.01). None of these inhibitors had a significant effect on NPR-C mRNA
when studied alone (Fig. 7). To be
certain that the inhibition observed with curcumin was not related to
an effect of this drug on EGF-R tyrosine kinase that has been
previously described (23), we examined whether curcumin
utilized under similar conditions modified EGF-R tyrosine kinase
phosphorylation by using the Western blot technique. No change was
observed compared with control (results not shown).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 6.
NPR-C mRNA levels in mesangial cells from D-NOD mice that
had been pretreated or not with EGF (5 ng/ml) during 2 or 4 h.
Top: a typical autoradiogram of polyacrylamide gel
electrophoresis. Bottom: NPR-C mRNA normalized to -actin
mRNA to account for the changes in the amount of cell RNA studied in
each lane. The average results of 4 experiments are shown. Each bar
represents the mean ± SE of the ratio of NPR-C to -actin mRNA.
Pretreatment with EGF significantly decreased this ratio after 2 and
4 h. C, control; *P < 0.05 vs. control.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 7.
The ANP clearance receptor (NPR-C) mRNA levels in mesangial
cells from D-NOD mice that had been pretreated or not with EGF (5 ng/ml) during 2 h with or without AG-1478 (AG; 250 nM) or curcumin
(Cur; 20 µM). Top: a typical autoradiogram of
polyacrylamide gel electrophoresis. Bottom: average results
of 4-5 experiments. Each bar represents the mean ± SE of the
ratio of NPR-C to -actin mRNA related to control. Pretreatment with
EGF significantly decreased this ratio (*P < 0.01 vs.
control) whereas AG-1478 and curcumin were inactive when studied alone.
In contrast, the latter 2, when studied in combination with EGF,
significantly reduced its inhibitory effect (#P < 0.01 vs. EGF alone).
|
|
Effect of EGF on the transcription factor AP-1.
The electrophoretic mobility gel-shift assay demonstrated that EGF (5 ng/ml) increased the binding activity of the transcription factor AP-1,
a heterodimer made of c-fos and c-jun, as shown by the increased
density of the complex of AP-1 present in the nuclear proteins with its
labeled oligonucleotide binding site. Addition of curcumin (20 µM) to
the incubation medium attenuated the effect of EGF. The binding of
nuclear proteins to the AP-1-responsive element was specific because
the decreased mobility of the radioactive complex was reversed by
incubation with a molar excess (200×) of unlabeled AP-1 binding site
(Fig. 8).

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 8.
Autoradiogram of a gel-shift assay with labeled
double-stranded oligonucleotide containing activator protein-1 (AP-1)
site and nuclear extracts of D-NOD mesangial cells that had been
treated with EGF (E) or EGF plus curcumin (E+Cur). NS, nonspecific
(addition of an excess of unlabeled nucleotide); arrow, position of the
labeled complex of AP-1 and AP-1 binding site.
|
|
Comparison of HB-EGF and EGF-R mRNA expression in D-NOD and ND-NOD
mesangial cells.
Because EGF or HB-EGF treatment diminished NPR-C density at the surface
of D-NOD mesangial cells, we raised the hypothesis that the greater
expression of NPR-C in D-NOD mesangial cells compared with ND-NOD
mesangial cells could be due to the lower expression, in the former, of
HB-EGF or EGF-R, which both are constitutively expressed in mouse
mesangial cells (34, 10). To examine this issue, we
measured by RNase protection assay the mRNA expression of these two
products. There was no difference in HB-EGF mRNA as shown by the
identical values of the ratio of HB-EGF to
-actin mRNA found in both
cell types (0.64 ± 0.38 and 0.65 ± 0.48 in ND-NOD and D-NOD
cells, respectively). In contrast, EGF-R mRNA expression was
significantly greater (P < 0.01) in D-NOD cells than
in ND-NOD cells. The ratio of EGF-R to
-actin mRNA was two times
more elevated in D-NOD mesangial cells (0.97 ± 0.04 vs. 0.51 ± 0.04). Of note, this difference was not in the direction that could
have supported our hypothesis (Fig. 9).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 9.
EGF receptor (EGF-R) and HB-EGF mRNA levels in mesangial
cells from ND-NOD (ND) and D-NOD (D) mice. Top: typical
autoradiograms of polyacrylamide gel electrophoresis for both
transcripts. Bottom: EGF-R and HB-EGF mRNA normalized to
-actin mRNA to account for the changes in the amount of cell RNA
studied in each lane. The average results of 4 experiments are shown.
Each bar represents the mean ± SE of the ratio of EGF-R or HB-EGF
mRNA to -actin mRNA. EGF-R mRNA expression was significantly
increased in D-NOD mesangial cells. **P < 0.01 vs.
ND-NOD mesangial cells.
|
|
 |
DISCUSSION |
These studies demonstrate for the first time that NPR-C mRNA and
receptor number are downregulated by EGF and the apparented peptide
HB-EGF, which shares the same receptor with EGF (40) and
is synthesized in cultured mesangial cells (36). In
contrast, other growth factors such as PDGF and IGF-I were inactive.
D-NOD mesangial cells were considered to be an ideal preparation
because they overexpressed NPR-C constitutively, which facilitated the study of their regulation. The mechanism of the inhibitory effect of
EGF implicates activation of its receptor tyrosine kinase and of the
transcription factor AP-1. A secondary goal of our studies was to
examine whether there were phenotypic changes in HB-EGF production or
EGF-R expression in D-NOD mesangial cells that could explain NPR-C
upregulation found in these cells compared with their ND-NOD counterpart.
Cultured D-NOD mesangial cell incubation with EGF or HB-EGF produced
time- and concentration-dependent decreases in 125I-ANP
binding. Decreased binding was not due to a decrease in cell viability,
as shown by the normal proliferative response to EGF, but to a marked
reduction in the density of the receptor sites with unchanged affinity.
EGF was efficient from a concentration of 1 ng/ml, which lies in the
range of normal plasma concentrations in humans (10),
suggesting that such an event could occur physiologically and also that
EGF is one of the inhibitory factors present in serum. The role of
serum in the regulation of NPR-C expression previously reported by Paul
et al. (31) in rat mesangial cells was confirmed in this
study. Serum-inhibitory influence was also apparent from the results of
the time course studies, which showed a progressive increase with time
of 125I-ANP binding to D-NOD mesangial cells after these
cells were deprived of serum. Because EGF modified 125I-ANP
Bmax but not KD and incubations of
several hours were necessary to alter ANP binding, it was likely that
the EGF effect occurred via a decrease in protein synthesis. To test
this hypothesis, we measured NPR-C mRNA levels by a nuclease protection
assay. There was a 40% decrease in NPR-C mRNA expression after 2- or 4-h incubation of D-NOD cells with EGF, thus confirming that this growth factor affected NPR-C synthesis. This time course is in accordance with that reported by Kishimito et al. (22) in
vascular smooth muscle cells. Our data did not allow us to decide
between an effect of EGF on the transcription rate as shown in the
latter study or on the stability of NPR-C mRNA. However, it excluded a
translational effect, as reported previously for dexamethasone (3) and thrombin (44). We did not study a
possible effect of EGF on NPR-A and NPR-B mRNA which we thought to be
unlikely, first because EGF did not modify the maximum ANP-dependent
cGMP production and, second, because the fraction of ANP binding
corresponding to the NPR-A receptors did not change in the presence of
EGF. In addition, the marked decrease (
70%) in ANP binding after
treatment of D-NOD cells with EGF could only be explained by the
predominant effect of this growth factor on NPR-C, which represents
90% of the total amount of ANP receptor sites in mouse mesangial cells (4).
EGF-dependent NPR-C downregulation was mediated by EGF-R because
HB-EGF reproduced the same effect, although with a lower affinity than
EGF and also because pretreatment of D-NOD mesangial cells with
tyrphostin AG-1478, a potent and specific inhibitor of EGF-R tyrosine
kinase, counteracted the influence of EGF on NPR-C mRNA expression. The
latter result was in accordance with the well-known tyrosine kinase
activity of EGF-R (40). In contrast, GF-109203X, a
potent and selective inhibitor of PKC, did not modify the EGF-dependent
downregulation of NPR-C mRNA. This indicates that PKC did not mediate
the EGF effect. A similar conclusion was reported by Zlock et al.
(44) for the effect of thrombin on NPR-C in cultured
bovine endothelial cells. However, this does not exclude a possible
role for PKC in the signal transduction of other agents also
controlling NPR-C expression. The latter hypothesis is supported by our
finding of the inhibitory role of PMA, a classic agonist of PKC, on
125I-ANP binding to D-NOD mesangial cells, in agreement
with the previous report by Paul et al. (30). In addition,
PMA could stimulate HB-EGF production in D-NOD cells as shown in rat
mesangial cells by Tan et al. (37).
Investigation of the MAP kinase cascade provided negative results, as
shown by the lack of effect of PD-98059. This differs from several
other studies in which EGF signal was transduced via this pathway
(40). We could also exclude the stimulation of PI3-kinase,
which has been shown as a downstream effector of EGF-R
(33) because wortmannin, considered to be a unique probe for this enzyme, did not counteract the inhibitory effect of EGF. Because a putative AP-1-responsive element has been identified in the
5'-flanking regulatory region of the mouse gene encoding NPR-C
(42), we tested the possibility that the transcription factor AP-1, an heterodimer of c-fos and c-jun, was implicated in the
EGF-dependent NPR-C downregulation. Curcumin, an inhibitor of several
transcription factors such as AP-1, nuclear factor-
-B, and Egr-1,
restored the NPR-C mRNA signal in the presence of EGF. However, the
meaning of this result could be questioned due to the broad specificity
of curcumin, which includes EGF-R tyrosine kinase (23).
Therefore, we also searched for a direct effect of EGF on AP-1. Using
the gel retardation assay, we could show that EGF increased the binding
of nuclear proteins to the labeled AP-1-responsive element. Moreover,
we verified, using the Western blot technique that curcumin, when
utilized under similar conditions of concentration and time of exposure
of the cells, did not modify the degree of phosphorylation of EGF-R.
Taken together, these results suggest what could be the pathway leading
from EGF-R activation to DNA transcription. Another pathway from those
of MAP kinases, PI3- kinase, or PKC, but one capable of activating
AP-1, must be implicated. This could be the jun
NH2-terminal kinase pathway, which leads to the expression
of c-jun, one of the subunits of the AP-1 complex. This pathway shunts
the ERK-1/ERK-2 step and has been shown as mediating the EGF-induced
expression of human 12-lipoxygenase (12). Because AP-1
mediates the long-term effects of vasoconstrictor peptides in mesangial
and vascular smooth muscle cells and ANG II acts in part through
transactivation of the EGF signaling pathway, one can hypothesize a
similar mechanism for the downregulation of NPR-C by ANG II
(11).
NPR-C have been postulated to play an essential role in the local
removal of ANP from the circulation, thus modulating its local
concentration (25). Such a mechanism should affect, in parallel, its biological effects. In our study, EGF did not change the
cGMP response to high stimulatory concentrations of ANP (10 nM)
probably due to the saturation of both subtypes of receptors, NPR-A and
NPR-C, by ANP under such conditions. In contrast, EGF stimulated cGMP
production by D-NOD mesangial cells exposed to lower doses of ANP (0.1 and 1 nM). These results suggest that EGF increased cGMP production by
downregulating NPR-C expression, thus allowing a greater availability
of ANP for its binding to NPR-A. A similar mechanism has been proposed
for bFGF in ovine fetoplacental artery endothelial cells
(19) and for
2-adrenergic stimulation in
vascular smooth muscle cells (22). Supplementary studies
are needed to better analyze the physiological importance of this
EGF-induced modulation of NPR-C in mesangial cells. EGF synthesis has
been shown to be upregulated in experimental diabetes (21,
35) and could thus facilitate the glomerular effects of ANP, in
particular the increase in GFR that is characteristic of the early
stages of diabetes mellitus (29). Reciprocally, Dhaunsi
and Hassid (13) observed that ANP and C-type natriuretic peptide amplified EGF activity in aortic smooth muscle cells
(13). These data strongly suggest that EGF and natriuretic
peptides are interregulated. This is particularly important to consider in diabetes mellitus, where both systems are activated simultaneously (21, 35 ). It is possible that the intrarenal levels of
growth factors and, especially of EGF, in association with vasoactive peptides contribute to the pathogenesis of glomerular microvascular lesions in this disease.
Another goal of this study was to examine whether a phenotypic change
in HB-EGF synthesis or in EGF-R expression in D-NOD mesangial cells
could be involved in the mechanism of the overexpression of NPR-C
observed in these cells. Our results confirm that HB-EGF is synthesized
by mouse mesangial cells, as shown by HB-EGF mRNA expression. Similar
findings were reported by Takemura et al. (36) in rat
mesangial cells. However, there was no difference between HB-EGF mRNA
expression in D-NOD and ND-NOD mesangial cells. Thus it was not
possible to associate diminished production of HB-EGF with the
upregulation of NPR-C in the same cells. We also provided evidence for
the presence of EGF-R in mouse mesangial cells, which is in accordance
with previously published reports of biological effects of EGF
(8, 18) and of EGF-R expression (36) in
mesangial cells. Of note, there was an upregulation of EGF-R mRNA in
D-NOD cells compared with ND-NOD cells. Such a finding excludes the
possible implication of modified EGF-R expression in the overexpression
of NPR-C in D-NOD cells. However, it is in accordance with other
studies reporting the upregulation of EGF-R in various preparations
from several diabetic animal models (21, 35).
Thus we have shown that EGF downregulated NPR-C expression in mouse
mesangial cells and, more particularly, in D-NOD mesangial cells, where
this NPR subtype is overexpressed through a mechanism implicating EGF-R
and AP-1. The direct consequence of this effect is to stimulate cGMP
formation in the same cells via a better availability of natriuretic
peptide at concentrations close to those observed under normal or
pathological conditions. On the basis of these findings, regulation of
NPR-C could have an important involvement in second messenger pathways
and the resulting biological effects of ANP on mesangial cells
including contractility and rate of proliferation (18).
 |
ACKNOWLEDGEMENTS |
This study was supported by grants from the Institut National de la
Santé et de la Recherche Médicale and the Faculté de Médecine Saint-Antoine.
 |
FOOTNOTES |
Address for reprint requests and other correspondence: R. Ardaillou, INSERM 489, Hôpital Tenon, 4 rue de la Chine, 75020 Paris cedex 20, France (E-mail:
raymond.ardaillou{at}tnn.ap-hop-paris.fr).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 6 February 2001; accepted in final form 16 April 2001.
 |
REFERENCES |
1.
Abraham, JA,
Damm D,
Bajurdi A,
Miller J,
Klogsbrun M,
and
Ezekowitz RA.
Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species and transcript expression in tissues.
Biochem Biophys Res Commun
190:
125-133,
1993[ISI][Medline].
2.
Alonso, S,
Minty A,
Bourlet Y,
and
Buckingham M.
Comparison of three actin-coding sequences in the mouse: evolutionary relationships between the actin genes of warm-blooded vertebrates.
J Mol Evol
23:
11-22,
1986[ISI][Medline].
3.
Ardaillou, N,
Blaise V,
Placier S,
Amestoy F,
and
Ardaillou R.
Dexamethasone upregulates ANP C-receptor protein in human mesangial cells without affecting mRNA.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F440-F446,
1996[Abstract/Free Full Text].
4.
Ardaillou, N,
Placier S,
Striker L,
Striker G,
and
Ardaillou R.
Mesangial cells from diabetic NOD mice constitutively express increased density of atrial natriuretic peptide C receptors.
Kidney Int
55:
1293-1302,
1999[ISI][Medline].
5.
Ardaillou, N,
Placier S,
Wahbe F,
Ronco P,
and
Ardaillou R.
Release of cyclic nucleotides from the apical and basolateral poles of cultured human glomerular epithelial cells.
Exp Nephrol
1:
253-260,
1993[ISI][Medline].
6.
Ardaillou, R,
Ronco P,
Rondeau E,
and
Friedlander G.
Biology of renal cells in culture.
In: The Kidney (6th ed.), edited by Brenner BM.. Philadelphia, PA: Saunders, 2000, p. 93-191.
7.
Avivi, A,
Lax I,
Ullrich A,
Schlessinger J,
Givol D,
and
Morse B.
Comparison of EGF receptor sequences as a guide to study the ligand binding site.
Oncogene
6:
673-676,
1991[ISI][Medline].
8.
Bonventre, JV,
Gronich JH,
and
Nemenoff RA.
Epidermal growth factor enhances glomerular mesangial cell soluble phospholipase A2 activity.
J Biol Chem
265:
4934-4938,
1990[Abstract/Free Full Text].
9.
Bradford, MM.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding.
Anal Biochem
72:
248-251,
1976[ISI][Medline].
10.
Carpenter, G,
and
Wahl MM.
The epidermal growth family.
In: Handbook of Experimental Pharmacology. Berlin: Springer-Verlag, 1990, p. 69-171.
11.
Chabrier, PE,
Roubert P,
Lonchampt MO,
Plas P,
and
Braquet P.
Regulation of atrial natriuretic factor receptors by angiotensin II in rat vascular smooth muscle cells.
J Biol Chem
263:
13199-13202,
1988[Abstract/Free Full Text].
12.
Chen, BK,
Kung HC,
Tsai TY,
and
Chang WC.
Essential role of mitogen-activated protein kinase pathway and c-jun induction in epidermal growth factor-induced gene expression of human 12-lipoxygenase.
Mol Pharmacol
57:
153-161,
2000[Abstract/Free Full Text].
13.
Dhaunsi, GS,
and
Hassid A.
Atrial and C-type natriuretic peptides amplify growth factor activity in primary aortic smooth muscle cells.
Cardiovasc Res
31:
37-47,
1996[ISI][Medline].
14.
Dignam, JP,
Lebowitz R,
and
Roeder RG.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acid Res
11:
1475-1489,
1995[Abstract].
15.
Dudley, DT,
Pand L,
Decker SJ,
Bridges AJ,
and
Saltiel AR.
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Proc Natl Acad Sci USA
92:
7686-7689,
1995[Abstract].
16.
Fu, X,
and
Kampo MP.
E2a-Pbx1 induces aberrant expression of tissue-specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts.
Mol Cell Biol
17:
1503-1513,
1997[Abstract].
17.
Hannedouche, TP,
Delgado AG,
Gnionsahe DA,
Boitard C,
Lacour B,
and
Grunfeld JP.
Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes.
Kidney Int
37:
1126-1133,
1990[ISI][Medline].
18.
Harris, RC,
Hoover RL,
Jacobson HR,
and
Badr KF.
Evidence for glomerular actions of epidermal growth factor in the rat.
J Clin Invest
82:
1028-1039,
1988[ISI][Medline].
19.
Itoh, H,
Zheng J,
Bird IM,
Nakao K,
and
Magness RR.
Basic FGF decreases clearance receptors of natriuretic peptides in fetoplacental artery endothelium.
Am J Physiol Regulatory Integrative Comp Physiol
277:
R541-R547,
1999[Abstract/Free Full Text].
20.
Iwasaki, H,
Egel S,
Ueno H,
Marumo F,
and
Hirata Y.
Endothelin-mediated vascular growth requires p42/44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor.
Endocrinology
140:
4659-4668,
1999[Abstract/Free Full Text].
21.
Khan, AJ,
Fligiel SE,
Liu L,
Jaszewski R,
Chandok A,
and
Majumdar AP.
Induction of EGFR tyrosine kinase in the gastric mucosa of diabetic rats.
Proc Soc Exp Biol Med
221:
105-110,
1999[Abstract].
22.
Kishimoto, I,
Yoshimasa T,
Suga S,
Ogawa Y,
Komatsu Y,
Nagagawa O,
Itoh H,
and
Nakao K.
Natriuretic peptide clearance receptor is transcriptionally down-regulated by beta 2-adrenergic stimulation in vascular smooth muscle cells.
J Biol Chem
269:
28300-28308,
1994[Abstract/Free Full Text].
23.
Korutla, L,
and
Kumar R.
Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells.
Biochim Biophys Acta
1224:
597-600,
1994[ISI][Medline].
24.
Levitzki, A,
and
Gazli A.
Tyrosine kinase inhibition: an approach to drug development.
Science
267:
782-1787,
1995[ISI].
25.
Maack, T.
Role of atrial natriuretic factor in volume control.
Kidney Int
49:
1732-1737,
1996[ISI][Medline].
26.
Mené, P,
Simonson MS,
and
Dunn MJ.
Physiology of the mesangial cell.
Physiol Rev
69:
1347-1424,
1989[Free Full Text].
27.
Munson, PJ,
and
Rodbard D.
Ligand: a versatile computerized approach for characterization of ligand-binding systems.
Anal Biochem
107:
220-239,
1980[ISI][Medline].
28.
O'Bryan, GT,
and
Hostetter TH.
The renal hemodynamic basis of diabetic nephropathy.
Semin Nephrol
17:
93-100,
1997[ISI][Medline].
29.
Ortola, FV,
Ballermann BJ,
Anderson S,
Mendez RE,
and
Brenner BM.
Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration.
J Clin Invest
80:
670-674,
1987[ISI][Medline].
30.
Paul, RV,
Wackym PS,
and
Budisavljevic MN.
Destabilization of natriuretic peptide C-receptor mRNA by phorbol myristate acetate.
J Am Soc Nephrol
9:
26-32,
1998[Abstract].
31.
Paul, RW,
Wackym PS,
Budisavljevic M,
Everett E,
and
Norris JE.
Regulation of atrial natriuretic peptide clearance receptors in mesangial cells by growth factors.
J Biol Chem
268:
18205-18212,
1993[Abstract/Free Full Text].
32.
Pendurthi, UR,
Williams JT,
and
Rao, IV
Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1 and NF-
B.
Arterioscler Thromb Vasc Biol
17:
3406-3413,
1997[Abstract/Free Full Text].
33.
Rodrigues, GA,
Falasca M,
Zhang Z,
Ong SH,
and
Schlessinger J.
A novel positive feedbackloop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.
Mol Cell Biol
20:
1448-1459,
2000[Abstract/Free Full Text].
34.
Roy-Chaudhury, P,
Jones MC,
MacLeod AM,
Haites NE,
Simpson JG,
and
Power DA.
An immunohistological study of epidermal growth factor receptor and new receptor expression in proliferative glomerulonephritis.
Pathology
25:
327-332,
1993[ISI][Medline].
35.
Sayed-Ahmed, N,
Besbas N,
Mundy J,
Muchanata-Kubara E,
Cope G,
Pearson C,
and
El Nahas M.
Upregulation of epidermal growth factor and its receptor in the kidneys of rats with streptozotocyn-induced diabetes.
Exp Nephrol
4:
330-339,
1996[ISI][Medline].
36.
Takemura, T,
Murata Y,
Hino S,
Okada M,
Yanajida H,
Ikeda M,
and
Yoshioka K.
Heparin-binding EGF-like growth factor is expressed by mesangial cells and is involved in mesangial proliferation in glomerulonephritis.
J Pathol
189:
431-438,
1999[ISI][Medline].
37.
Tan, MS,
Tsai JC,
Lee YJ,
Chen HC,
Shin SJ,
Lai YH,
Perrella MA,
Bianchi C,
Higashiyama S,
and
Endege W.
Induction of heparin-binding epidermal growth factor-like growth factor mRNA by protein kinase C activators.
Kidney Int
46:
690-695,
1994[ISI][Medline].
38.
Toullec, D,
Pianetti P,
Coste H,
Bellevergue P,
Grand-Perret T,
Ajakane M,
Baudet V,
Boissin P,
Boursier E,
Loriolle F,
Duhamel L,
Charon D,
and
Kirilovsky J.
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
J Biol Chem
266:
15771-15781,
1991[Abstract/Free Full Text].
39.
Ui, M,
Okada T,
Hazeki K,
and
Hazeki O.
Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase.
Trends Biochem Sci
20:
303-307,
1995[ISI][Medline].
40.
Van der Geer, P,
Hunter T,
and
Lindberg RA.
Receptor protein-tyrosine kinases and their signal transduction pathways.
Annu Rev Cell Biol
10:
251-337,
1994[ISI].
41.
Wolf, G,
and
Ziyadeh FN.
Molecular mechanisms of diabetic renal hypertrophy.
Kidney Int
56:
393-405,
1999[ISI][Medline].
42.
Yanaka, N,
Kotera J,
Taguchi I,
Sugiara M,
Kawashima K,
and
Omori K.
Structure of the 5'-flanking regulatory region of the mouse gene encoding the clearance receptor for atrial natriuretic peptide.
Eur J Biochem
237:
25-34,
1996[Abstract].
43.
Zhang, LM,
Tao H,
and
Newman WH.
Regulation of atrial natriuretic peptide receptors in vascular smooth muscle cells: role of cGMP.
Am J Physiol Heart Circ Physiol
264:
H1753-H1759,
1993[Abstract/Free Full Text].
44.
Zlock, DW,
Cao L,
Wa J,
and
Gardner DG.
Thrombin inhibits atrial natriuretic peptide receptor activity in cultured bovine endothelial cells.
Hypertension
29:
83-90,
1997[Abstract/Free Full Text].
Am J Physiol Renal Fluid Electrolyte Physiol 281(2):F244-F254
0363-6127/01 $5.00
Copyright © 2001 the American Physiological Society